Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Although these results of this study are very significant, they arent a great surprise
Evaluation: Body fat (DXA scanning) Lean mass Insulin sensitivity Energy expenditure What they found: The combination showed an additive effect on fat reduction vs monotherapy AOD-9604 partially protected lean mass during GLP-1-induced weight reduction Increased energy expenditure in combination (~3 % vs GLP-1 alone) No new safety signals Why it matters: It validates the concept of combination , the idea that AOD-9604 may not work on its own, but can add value in combination with incretin agonists
A cross-over study vs placebo
The tirzepatide pen is specifically designed to deliver medication into the subcutaneous tissue when used according to the FDA-approved Instructions for Use
While tirzepatide is primarily approved for type 2 diabetes, it has shown promising results in weight management , making it highly relevant for patients seeking aesthetic improvements and enhanced body contouring results
Laboratory interference: Persistent unexplained elevation may reflect macro-B12 (immunoglobulin-bound B12) or other assay interferences
US$ 24.06
US$ 22.57
US$ 29.64
US$ 23.25
US$ 23.83
US$ 24.23
